What are imatinib and other TKIs?
Imatinib is a targeted cancer medicine taken as a daily tablet. It belongs to a group called tyrosine kinase inhibitors (TKIs), which block abnormal enzymes (kinases) that drive certain cancers to grow. Imatinib transformed the treatment of two very different cancers: chronic myeloid leukaemia (CML), a blood cancer, and gastrointestinal stromal tumour (GIST), a type of sarcoma that usually starts in the stomach or small bowel.
Before imatinib, CML usually progressed to a fatal acute leukaemia within a few years unless a donor stem cell transplant was possible. Today, most people with chronic-phase CML who take a TKI can expect a near-normal life expectancy. Advanced GIST, which does not respond to standard chemotherapy, also became treatable with tablets.
Imatinib was the first of these drugs. Several others now exist, including dasatinib, nilotinib, bosutinib, ponatinib and asciminib for CML, and sunitinib, regorafenib, ripretinib and avapritinib for GIST.
A brief history
The Philadelphia chromosome was first described in 1960, in the city that gave it its name. Over the following decades, scientists showed that it creates the BCR-ABL1 fusion gene. Imatinib was designed to block this exact target, and early trials around the year 2000 showed striking responses. It was approved for CML in 2001 and for GIST in 2002, and is often cited as the first great success of precision cancer medicine.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Targeted therapy (kinase inhibitors) |
| Main uses | Chronic myeloid leukaemia, GIST, Philadelphia-positive acute lymphoblastic leukaemia |
| How it is given | Tablets taken once or twice a day at home |
| Course length | Often many years; for GIST after surgery, usually 3 years |
| Monitoring | Blood tests (BCR-ABL1 PCR) for CML; scans for GIST |
| Common side effects | Swelling around the eyes, muscle cramps, nausea, diarrhoea, tiredness, rash |
| Possibility of stopping | Some people with CML in deep, lasting remission can stop treatment |
2. How it works
The targets
| Cancer | Abnormal gene | What goes wrong |
|---|---|---|
| CML | BCR-ABL1 (from the Philadelphia chromosome) | Two chromosomes swap pieces, creating a fused gene whose kinase is permanently switched on |
| GIST | KIT or PDGFRA | A mutation turns on a growth receptor all the time |
Kinases work by attaching a phosphate group (taken from ATP) to other proteins, passing on a “grow” signal. Imatinib fits into the ATP-binding pocket of the BCR-ABL1, KIT and PDGFRA kinases, blocking them. Without the signal, the cancer cells stop dividing and many die.
Generations of TKIs in CML
| Generation | Drugs | Key features |
|---|---|---|
| First | Imatinib | Long track record; available as cheaper generic |
| Second | Dasatinib, nilotinib, bosutinib | Faster and deeper responses; different side effect patterns |
| Third | Ponatinib | Active against the T315I resistance mutation |
| Allosteric | Asciminib | Binds a different site on the kinase (the myristoyl pocket) |
TKIs in GIST
| Line of treatment | Typical drug |
|---|---|
| First | Imatinib (avapritinib for PDGFRA D842V mutation) |
| Second | Sunitinib |
| Third | Regorafenib |
| Fourth | Ripretinib |
TKIs belong to the wider family of kinase inhibitors, which also includes drugs such as the TRK inhibitors larotrectinib and entrectinib.
3. Who it is for
Conditions treated
| Condition | Role of TKIs |
|---|---|
| Chronic myeloid leukaemia | Standard first-line treatment for chronic phase |
| Gastrointestinal stromal tumour | After surgery for higher-risk tumours; main treatment for advanced disease |
| Acute lymphoblastic leukaemia | Philadelphia-positive ALL, combined with chemotherapy or other drugs |
| Mixed phenotype acute leukaemia | When the BCR-ABL1 fusion is present |
| Dermatofibrosarcoma protuberans | Imatinib for advanced or inoperable tumours |
| Chronic eosinophilic leukaemia | Imatinib for cases with PDGFRA or PDGFRB rearrangements |
| Systemic mastocytosis | Other kinase inhibitors such as avapritinib or midostaurin; imatinib only in rare KIT types |
Phases of CML
| Phase | Description | TKI role |
|---|---|---|
| Chronic phase | Most people are diagnosed here; few immature cells in the blood | TKIs usually give long-term control |
| Accelerated or advanced phase | More immature cells; disease becoming harder to control | Stronger TKIs; transplant may be considered |
| Blast phase | Behaves like acute leukaemia | TKIs plus chemotherapy, often followed by transplant |
GIST risk after surgery
The chance of GIST returning after surgery depends on the tumour size, how quickly its cells divide (the mitotic rate), its location (stomach GISTs tend to behave better than small bowel GISTs) and whether the tumour ruptured. The mutation type also matters: some mutations respond well to imatinib, while others, such as PDGFRA D842V, do not.
Who may need extra care
| Situation | Consideration |
|---|---|
| Heart disease | Some TKIs affect the heart or blood vessels |
| Lung problems | Dasatinib can cause fluid around the lungs |
| Diabetes or high cholesterol | Nilotinib can affect blood sugar and cholesterol |
| Liver disease | Most TKIs are processed by the liver |
| Pregnancy | TKIs should be avoided; plans need specialist input |
4. Before treatment
| Step | Why it is done |
|---|---|
| Confirm diagnosis | Philadelphia chromosome and BCR-ABL1 for CML; KIT or PDGFRA testing for GIST |
| Risk scoring | Helps choose the drug and plan monitoring |
| Blood tests | Blood counts, kidney and liver function, blood sugar, cholesterol |
| Heart tracing (ECG) | Some TKIs affect heart rhythm |
| Medicines review | Many drugs and grapefruit interact with TKIs |
| Fertility and pregnancy plans | TKIs can harm a developing baby |
5. What to expect: step by step
CML
| Step | What happens |
|---|---|
| 1. Starting tablets | Taken at home; imatinib with food and a large glass of water |
| 2. Early blood tests | Every 1-2 weeks at first to check blood counts |
| 3. Molecular monitoring | BCR-ABL1 PCR every 3 months |
| 4. Milestones | Levels at 3, 6 and 12 months show whether the drug is working |
| 5. Switching | A different TKI is chosen for intolerance or poor response |
| 6. Deep response | Over years, many reach very low or undetectable levels |
| 7. Possible stopping | After a long, deep response, some can try treatment-free remission |
European guidance states that a BCR-ABL1 level above 10% at 3 months, once confirmed, indicates treatment failure (Hochhaus et al., 2020).
GIST
| Step | What happens |
|---|---|
| 1. Surgery | For localised tumours, the tumour is removed first |
| 2. Risk assessment | Size, location, mitotic rate and rupture predict the chance of return |
| 3. Adjuvant imatinib | Usually 3 years for high-risk tumours |
| 4. Advanced disease | Imatinib continued as long as it works |
| 5. Scans | CT every 3-6 months |
| 6. Switching | Next-line TKIs if the tumour grows |
6. Side effects and risks
| Side effect | Most associated with | Notes |
|---|---|---|
| Swelling around the eyes and ankles | Imatinib | Common; usually mild |
| Muscle cramps and aches | Imatinib | Common; magnesium and fluids may help |
| Nausea | Imatinib | Take with food |
| Diarrhoea | Several TKIs | Usually mild |
| Rash | Several TKIs | Usually manageable |
| Tiredness | All | Common |
| Low blood counts | All, especially early | Monitored with blood tests |
| Fluid around the lungs | Dasatinib | Breathlessness should be reported |
| High blood sugar or cholesterol | Nilotinib | Regular checks |
| Narrowing of arteries | Nilotinib, ponatinib | Heart and circulation monitoring |
| Hand-foot skin reaction, high blood pressure | Sunitinib, regorafenib | Common in GIST treatment |
| Liver inflammation | Several TKIs | Liver tests |
In the first major GIST trial, mild to moderate swelling, diarrhoea and tiredness were common, and bleeding into the bowel or abdomen occurred in about 5% of people (Demetri et al., 2002).
7. Results and outlook
| Study | Main finding |
|---|---|
| IRIS, newly diagnosed CML (long-term follow-up) | Ten-year survival with imatinib was about 83%, and late serious side effects were uncommon (Hochhaus et al., 2017) |
| Imatinib in advanced GIST (147 people) | More than half had partial tumour shrinkage and about a quarter had stable disease (Demetri et al., 2002) |
| Adjuvant imatinib for high-risk GIST (400 people) | Three years of imatinib after surgery gave five-year survival of 92% compared with about 82% after one year (Joensuu et al., 2012) |
Treatment-free remission
One of the most remarkable developments in CML is that some people can stop their TKI. If BCR-ABL1 has stayed at very low levels for several years, stopping under close monitoring may be possible. About half of those who try remain in remission.
If levels rise, restarting the TKI almost always brings the disease back under control. European guidance supports considering this for people with a durable deep molecular response (Hochhaus et al., 2020).
8. Recovery and aftercare
Living with long-term tablets
| Tip | Why |
|---|---|
| Take tablets every day as prescribed | Missed doses are a common cause of poor response |
| Use reminders or pill boxes | Helps keep to a routine |
| Check before taking new medicines | Many common drugs interact |
| Avoid grapefruit and Seville oranges | They affect levels of several TKIs |
| Report side effects early | Doses can often be adjusted |
| Keep up blood tests and scans | They guide treatment |
Follow-up
| Check | CML | GIST |
|---|---|---|
| Blood counts | Regularly | Regularly |
| BCR-ABL1 PCR | Every 3 months, then every 3-6 months | Not applicable |
| CT scans | Not usually needed | Every 3-6 months |
| Heart and metabolic checks | Depending on the drug | Depending on the drug |
Pregnancy and family planning
Women with CML who want to become pregnant may be able to stop treatment under specialist care if their response is deep enough. Men taking imatinib can usually father children, but should discuss this with their team. Pregnancy should be planned in advance whenever possible.
Living well with CML or GIST
Many people with CML now live normal lives, work and travel while taking their tablets. Feeling well while still needing daily medicine can be emotionally complex. Patient groups for CML and sarcoma offer peer support, practical tips and up-to-date information.
Why taking every dose matters
Studies in CML have shown that people who miss doses regularly are less likely to reach deep responses. Small gaps add up over months. If side effects make it hard to keep taking your tablets, tell your team rather than skipping doses; a dose change or switch to another TKI may solve the problem.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Switching to another TKI | Intolerance or resistance |
| Allogeneic (donor) stem cell transplant | CML in advanced phase or resistant to several TKIs; unlike an autologous stem cell transplant, it uses donor cells |
| Surgery | Localised GIST; sometimes to remove resistant GIST deposits |
| Interferon | Occasionally in CML during pregnancy |
| Clinical trials | New drugs for resistant disease |
Cost and access
Generic imatinib is now widely available and much cheaper than when it was first launched. European guidance describes generic imatinib as a cost-effective first treatment for chronic-phase CML (Hochhaus et al., 2020). Newer TKIs may be reserved for people at higher risk or those who need to switch.
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is imatinib chemotherapy? | It is a targeted drug, not traditional chemotherapy |
| Will I lose my hair? | Hair loss is uncommon; some thinning or lightening can occur |
| Will I take it for life? | Many people do, but some with CML can stop |
| Can I drink alcohol? | Moderate amounts are usually fine; check with your team |
| What if I miss a dose? | Skip it and take the next one as normal; do not double up |
| Can I travel? | Yes; take enough tablets and a letter from your team |
| Can I take it with my other medicines? | Many are fine, but always check with your pharmacist first |
| Will generic imatinib work as well? | Generic versions are considered equally effective |
11. Questions to ask your care team
- Which TKI do you recommend for me, and why?
- What are the main side effects of this drug?
- How often will I need blood tests or scans?
- What milestones should my results reach?
- Which medicines or foods should I avoid?
- Could I ever stop treatment?
- What happens if the drug stops working?
Resources
- Demetri, G.D. et al. (2002) ‘Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors’, New England Journal of Medicine, 347(7), pp. 472-480.
- Hochhaus, A. et al. (2017) ‘Long-term outcomes of imatinib treatment for chronic myeloid leukemia’, New England Journal of Medicine, 376(10), pp. 917-927.
- Hochhaus, A. et al. (2020) ‘European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia’, Leukemia, 34(4), pp. 966-984.
- Joensuu, H. et al. (2012) ‘One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial’, JAMA, 307(12), pp. 1265-1272.
- National Cancer Institute (2026) Chronic Myeloid Leukemia Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq (Accessed: October 2026).
- National Cancer Institute (2026) Gastrointestinal Stromal Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.